Welcome to our dedicated page for PERKINELMER news (Ticker: PKI), a resource for investors and traders seeking the latest updates and insights on PERKINELMER stock.
PerkinElmer Inc. (PKI) drives innovation in diagnostics, life sciences, and applied markets through advanced scientific solutions. This page aggregates official announcements and verified news about the company's strategic initiatives, financial performance, and technological advancements.
Investors and industry professionals will find timely updates on earnings reports, product launches, and regulatory milestones. Our curated collection simplifies tracking PKI's progress in enabling critical research and improving healthcare outcomes globally.
Key content includes updates on analytical instrumentation developments, partnership announcements with research institutions, and expansions in diagnostic testing capabilities. All materials adhere to strict factual reporting standards without speculative commentary.
Bookmark this page for streamlined access to PerkinElmer's latest corporate communications. Check back regularly for insights into how PKI continues to address complex challenges in scientific discovery and clinical diagnostics.
PerkinElmer (NYSE: PKI) has introduced two new Research Use Only (RUO) solutions: PKamp™ VariantDetect™ SARS-CoV-2 RT-PCR Assay and Next Generation Sequencing-based NEXTFLEX® Variant-Seq™ SARS-CoV-2 Kit. These assays allow laboratories to analyze genomic mutations in SARS-CoV-2 variants from previously positive samples. The PKamp assay detects mutations related to dominant variants like B.1.1.7 and B.1.351, enhancing COVID-19 testing capabilities. PerkinElmer continues to innovate amidst evolving public health challenges.
PerkinElmer (NYSE: PKI) has priced a $400 million offering of 2.550% Senior Notes due 2031 and 3.625% Senior Notes due 2051. The offering, expected to close on March 8, 2021, aims to utilize approximately $561 million of net proceeds to repay debt related to its acquisition of Oxford Immunotec Global PLC and to refinance existing senior notes. This strategic move aligns with the company's focus on innovation and maintaining a healthy financial position.
PerkinElmer, Inc. (NYSE: PKI) will present at the Barclays Global Healthcare Conference on March 10, 2021, from 9:45 a.m. to 10:10 a.m. ET. The presentation will feature Prahlad Singh, president and CEO, discussing the Company's strategic priorities. Investors can access a live audio webcast of the event on PerkinElmer's website, with a replay available for 90 days post-event. In 2020, PerkinElmer reported revenues of approximately $3.8 billion, employs over 14,000 people, and serves clients in 190 countries, being part of the S&P 500 Index.
PerkinElmer (NYSE: PKI) has launched its COVID-19 Antigen Test for the qualitative detection of SARS-CoV-2 antigen, yielding results in 15 minutes. This test, suitable for professional use in various settings, is already available in over 30 countries. Clinical studies show a sensitivity rate exceeding 97% and 100% specificity, indicating no false positives. The company emphasizes the need for reliable antigen testing to support reopening strategies globally. The test complements PerkinElmer's existing portfolio, which includes high throughput RNA extraction and RT-PCR solutions.
PerkinElmer (NYSE: PKI) provided an update on the accreditation of its COVID-19 Valencia Branch Laboratory (VBL) in collaboration with the California Department of Public Health. The VBL commenced operations on November 1, 2020, and has capacity for 100,000 tests daily. Following a recent inspection, PerkinElmer addressed identified deficiencies and expects a positive response from the College of American Pathologists (CAP) accreditation. The laboratory has tested over 1.5 million samples. PerkinElmer emphasizes its commitment to quality and transparency throughout the accreditation process.
PerkinElmer, a leading global innovator, will present at the 41st Annual Cowen Health Care Conference on March 1, 2021, from 12:20 to 12:50 p.m. ET. CEO Prahlad Singh will discuss the company's strategic priorities. A live audio webcast will be available on the company's Investors page, with a replay accessible for 90 days after the event. In 2020, PerkinElmer reported approximately $3.8 billion in revenue and employs over 14,000 people across 190 countries, contributing to the S&P 500 Index.
PerkinElmer reported strong financial results for Q4 and the full year 2020. Q4 GAAP earnings per share were $3.38, up from $0.58 in Q4 2019. Revenue climbed to $1.355 billion from $805 million YoY. The full year saw GAAP EPS of $6.50, compared to $2.04 in 2019, with annual revenue reaching $3.783 billion, up from $2.884 billion. The Diagnostics segment thrived, with Q4 revenue up 176% to $852 million. For 2021, the company forecasts GAAP revenue of at least $4.08 billion and EPS of at least $6.73, reflecting continued growth.
The Board of Directors of PerkinElmer (NYSE: PKI) announced a quarterly dividend of $0.07 per share, payable on May 7, 2021. Shareholders on record as of April 16, 2021 will receive this dividend. PerkinElmer, a leader in health innovation, reported revenues of approximately $2.9 billion in 2019 and employs around 14,000 people globally, serving customers in 190 countries. The company is also a component of the S&P 500 Index.
PerkinElmer (NYSE:PKI) announced that its New Coronavirus Nucleic Acid Detection Kit has received Emergency Use Authorization (EUA) from the FDA for testing asymptomatic individuals. A significant finding indicates that nearly 60% of COVID-19 transmissions originate from asymptomatic carriers, highlighting the need for effective diagnostic testing. This test boasts the lowest Limit of Detection among authorized COVID-19 tests, making it highly sensitive. The company also offers sample pooling options, enhancing testing capabilities without additional resources.
PerkinElmer (NYSE: PKI) projects 66% reported and 63% organic revenue growth for Q4 2020, with GAAP EPS of at least $2.88 and adjusted EPS of at least $3.60. This robust performance is mainly due to increased demand for COVID-19 solutions, generating approximately $535 million in revenue. However, the non-COVID-19 segment saw a 3% organic decline. The financial results will be released on February 2, 2021, followed by a conference call at 5:00 p.m. ET.